Umoja Biopharma
Umoja Biopharma develops in vivo CAR T cell therapies that generate cancer-fighting T cells directly in a patient’s body. Its therapies are designed to treat cancers while making treatment more accessible by avoiding the multi-week cell manufacturing required for ex vivo CAR T therapies.
Facts
- HQ
- Seattle, WA 98109
- Sectors
- Biotechnology Research
- Founded
- 2019
- Type
- Corporation Seattle business license
- Employees
- 254
- Registered name
- Umoja Biopharma Inc Seattle business license
- Members see funding amounts. .
Is this your organization? Claim it
Umoja Biopharma Announces FDA Clearance of IND for UB-VV400, First Known CD22-Directed In Vivo CAR T for Relapsed/Refractory B Cell Malignancies
Umoja Biopharma received FDA clearance for its IND for UB-VV400, the company's lead in vivo CD22-directed CAR T therapy targeting relapsed/refractory B cell malignancies, advancing its clinical pipeline toward first patient dosing.
Umoja Biopharma to Unveil UB-VV500, First In Vivo BCMA × GPRC5D CAR T Therapy for Multiple Myeloma at ASGCT
Umoja Biopharma will present UB-VV500, the industry’s first in vivo CAR T therapy combining BCMA and GPRC5D targeting multiple myeloma, at the ASGCT annual meeting, highlighting its novel dual-antigen approach and planned poster data release.
Umoja Biopharma Appoints Dr. Marcela Maus and Dr. Athena Countouriotis to Board of Directors
Umoja Biopharma appointed Dr. Marcela Maus and Dr. Athena Countouriotis to its board of directors, expanding leadership with experienced biotech and cell therapy experts.
Umoja Biopharma Announces Death of Scientific Co-founder Dr. Philip Low, Honors His Legacy
Umoja Biopharma announces the death of its scientific co-founder Dr. Philip Low and honors his contributions as a pioneering scientist and entrepreneur.
Umoja Biopharma’s in vivo CAR T candidate UB-VV111 awarded FDA Fast Track designation for relapsed/refractory B‑cell malignancies
Umoja Biopharma says the FDA granted Fast Track designation to its in vivo CAR T candidate UB-VV111 for relapsed/refractory B‑cell malignancies, advancing the therapy’s development pathway and regulatory support.
People
-
Andy Scharenberg Executive Officer, Director, Co-founder & Chief Executive Officer
-
Michael Jensen Co-Founder
-
Nate Hardy Executive, Chief Financial Officer